Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Abera Bioscience AB, a biopharmaceutical company, specializes in the research and development of modern vaccines and vaccine technology platforms. The primary focus of this Swedish company is to improve public health through innovative solutions targeting infectious diseases. Abera Bioscience AB leverages its proprietary BERA platform, which facilitates the rapid development and production of protein-based vaccines. This technology has the potential to impact various sectors, including healthcare, pharmaceuticals, and biotechnology, by offering tools for the creation of effective and accessible vaccines. In the financial markets, Abera Bioscience AB plays a pivotal role by contributing to the growing demand for scalable and adaptable vaccine technologies, which are essential in the fight against outbreaks and pandemics.
kr 0.72
kr 0.10 (-11.74%)
EOD Jun 23, 2026 · Twelve Data
ROIC dropped from -14.78% to -60.01%, capital efficiency is deteriorating. Negative free cash flow of -kr 4M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 16M
▼ -850.3% YoY
Op. Margin
—
ROIC
-60.01%
▼ -45.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 11M
▼ -177.2% YoY
Op. Cash Flow (TTM)
-kr 10M
▼ -1166.7% YoY
Net Debt
-kr 23M
Net Cash Position
Cash & Equiv.
kr 23M
Continue Research
Abera Bioscience AB (ABERA.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Abera Bioscience AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Abera Bioscience AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -60.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ABERA.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.